drugset / Trial / NCT02815644
Empa/Lina FDC Food Effect Study (Japan)
RandomizedCrossoverOpen-labelTreatment
Summary
The trial will be performed as an open-label, randomised, single-dose, two-sequence crossover design for the assessment of effect of food on bioavailability of empagliflozin / linagliptin fixed dose combination (FDC) tablet.
Timeline
- Start
- 2016-07-15
- Primary completion
- 2016-10-05
- Completion
- 2016-10-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | — | — |
| Subject | Linagliptin | Small molecule | — | — |
Indications
No indication recorded.